Effect of levetiracetam in refractory childhood epilepsy syndromes

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Pharmacology

Background:

• Childhood epilepsy syndromes often present as refractory to standard treatments.
• Identifying effective add-on therapies is crucial for managing seizure frequency and improving quality of life in affected children.

Purpose of the Study:

• To evaluate the efficacy and tolerability of levetiracetam as an add-on therapy in children with refractory epilepsy syndromes.
• To assess the impact of rapid dose escalation of levetiracetam on seizure frequency.

Main Methods:

• An open-label, add-on study involving 21 children with refractory partial and generalized seizures.
• Levetiracetam was initiated at 10 mg/kg/day and rapidly escalated by 10 mg/kg every 4 days, up to 60 mg/kg/day.
• Seizure frequency was monitored to assess treatment response and tolerability.

Main Results:

• 47% of participants experienced a greater than 50% reduction in seizure frequency.
• Levetiracetam demonstrated efficacy in both partial and generalized seizures, with a notable effect on myoclonic seizures.
• Mild side effects were reported in only four children at dosages exceeding 40 mg/kg/day.

Conclusions:

• Rapid introduction of levetiracetam is an effective add-on strategy for managing refractory childhood epilepsy.
• Levetiracetam is well-tolerated and shows significant efficacy across various seizure types in this pediatric population.